Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Work In Process (2016 - 2018)

Anika Therapeutics has reported Work In Process over the past 8 years, most recently at $5.9 million for Q3 2018.

  • Quarterly Work In Process fell 9.38% to $5.9 million in Q3 2018 from the year-ago period, while the trailing twelve-month figure was $5.9 million through Sep 2018, down 9.38% year-over-year, with the annual reading at $6.1 million for FY2017, 9.05% up from the prior year.
  • Work In Process was $5.9 million for Q3 2018 at Anika Therapeutics, down from $6.3 million in the prior quarter.
  • Over five years, Work In Process peaked at $6.6 million in Q3 2017 and troughed at $2.2 million in Q2 2014.
  • The 5-year median for Work In Process is $5.6 million (2016), against an average of $4.8 million.
  • Year-over-year, Work In Process surged 94.43% in 2016 and then fell 9.38% in 2018.
  • A 5-year view of Work In Process shows it stood at $3.0 million in 2014, then soared by 85.99% to $5.7 million in 2015, then dropped by 1.71% to $5.6 million in 2016, then increased by 9.05% to $6.1 million in 2017, then dropped by 1.88% to $5.9 million in 2018.
  • Per Business Quant, the three most recent readings for ANIK's Work In Process are $5.9 million (Q3 2018), $6.3 million (Q2 2018), and $5.9 million (Q1 2018).